Skip to content

Minimally Invasive Surgery (MIS) for Spine Metastases

Minimally Invasive Surgery for Spine Metastases - A Prospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02367378
Enrollment
14
Registered
2015-02-20
Start date
2015-02-28
Completion date
2016-06-13
Last updated
2017-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spine Metastases

Keywords

Minimally invasive surgery

Brief summary

The purpose of this study is to collect information on the effect of minimally invasive spine tumor decompression on treated patients. This treatment option is less invasive that the standard surgical decompression and is expected to result in better wound healing, decreased tissue trauma, and decreased pain after surgery.

Detailed description

This is a prospective study designed to analyze the impact that minimally invasive spine tumor decompression has upon quality of life, neurological morbidity, pain, and mortality. Prospective findings will be compared with historical controls to determine whether the minimally invasive approach offers better outcomes than traditional treatment methods.

Interventions

None listed

Sponsors

Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* undergone minimally invasive surgery * over 18 years of age

Exclusion criteria

* unable to give consent

Design outcomes

Primary

MeasureTime frameDescription
Survival timeup to 2 yearsSurvival time in days

Secondary

MeasureTime frameDescription
Cobb Angleup to 2 yearsThe Cobb angle is used to quantify the magnitude of spinal deformities.
Ambulation Indexup to 2 yearsHauser Ambulation Index to assess mobility by evaluating the time and degree of assistance required to walk 25 feet. Scores range from 0 (asymptomatic and fully active) to 10 (bedridden).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026